



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO. /CONTROL NO. 10542184	FILING DATE 2/6/06	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION DAVIES ET AL.	ATTORNEY DOCKET NO. PC19486A
---	-----------------------	--	------------------------------------

EXAMINER
ZACHARY C. HOWARD

ART UNIT 1646	PAPER 20090218
------------------	-------------------

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825).

Specifically, the specification discloses nucleic acid sequences (primers) at page 19 (5 sequences); page 20 (3 sequences) and page 26 (8 sequences) that have not been submitted as part of a "Sequence Listing" as required by the sequence rules (37 CFR 1.821 - 1.825). The Examiner notes that no Sequence Listing has yet been filed in the instant application.

Therefore, Applicants must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) by submitting an initial computer-readable form (CRF) of a "Sequence Listing" containing each sequence disclosed in the specification and/or drawings; a paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application; and a statement that the content of the paper and CRF copies are the same, and include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Furthermore, the specification must be amended such that each sequence shown therein is accompanied by the appropriate corresponding sequence identifier.

APPLICANT IS GIVEN THREE MONTHS FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Web (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>>, EFS Submission User Manual - ePAVE)
2. Mailed to:

Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313 1450
Alexandria, VA 22313 1450

3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:

U.S. Patent and Trademark Office

Mail Stop Sequence

Customer Window

Randolph Building

401 Dulaney Street

Alexandria, VA 22314

Any inquiry concerning this communication should be directed to Zachary C. Howard at telephone number (571)272-2877. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary B. Nickol, can be reached on (571)272-0835.

/Bridget E Bunner/
Primary Examiner, Art Unit 1647